GlassScriptPhysician profile
Khoi Lang
NPI 1699167130
$11,975.50
in general payments reported to CMS, 2019-2025
35 companies · $2,950 in 2025
The $2,950 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,270 · 2022: $2,045 · 2023: $2,292 · 2024: $2,419 · 2025: $2,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,622 · Education: $39.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,621.66 |
| Education | $39.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,658.98 | 2021-2025 | |
| Janssen Biotech, INC. | $1,386.52 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,146.99 | 2021-2025 | Entyvio, Eohilia |
| Pfizer INC. | $448.90 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $437.48 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Regeneron Healthcare Solutions, INC. | $432.37 | 2022-2025 | Dupixent |
| Daiichi Sankyo INC. | $413.00 | 2021-2023 | Injectafer |
| Celgene Corporation | $410.47 | 2021-2024 | Zeposia |
| Genzyme Corporation | $404.73 | 2022-2024 | |
| Madrigal Pharmaceuticals | $389.31 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $340.21 | 2021-2023 | Linzess |
| Lilly USA, LLC | $299.96 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $225.39 | 2022-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $185.43 | 2025 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $182.39 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $163.99 | 2025 | Tremfya, Stelara |
| Celltrion USA INC. | $148.66 | 2024-2025 | Vegzelma, Zymfentra |
| Merck Sharp & Dohme LLC | $134.96 | 2021-2024 | Dificid |
| Amgen INC. | $134.63 | 2021-2023 | Avsola |
| E.R. Squibb & Sons, L.L.C. | $121.64 | 2023 | Zeposia |
| Qol Medical, LLC | $108.75 | 2022-2023 | Sucraid |
| Ardelyx, INC. | $103.81 | 2023-2024 | Ibsrela |
| Braintree Laboratories, INC. | $95.17 | 2021-2023 | Sutab |
| Phathom Pharmaceuticals, INC. | $87.35 | 2024 | Voquezna |
| Ferring Pharmaceuticals INC. | $86.75 | 2021-2023 | Clenpiq |
| Vivus LLC | $76.08 | 2022-2023 | Pancreaze, Qsymia |
| Alfasigma USA, INC. | $67.97 | 2021-2022 | |
| Redhill Biopharma INC. | $51.85 | 2021-2023 | Talicia |
| Organon LLC | $45.92 | 2022-2023 | Renflexis |
| Aimmune Therapeutics, INC. | $43.35 | 2024-2025 | Zenpep |
| Amag Pharmaceuticals, INC. | $35.63 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $34.67 | 2023 | |
| Fresenius Kabi USA, LLC | $34.16 | 2024 | Idacio |
| Alnylam Pharmaceuticals INC. | $25.72 | 2025 | Givlaari |
| Ethicon US, LLC | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khoi Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.